Anthony K. Shum

Anthony K. Shum

Auto-generated profile, based on publicly available information

Anthony K. Shum

Cardiovascular Research Institute, University of California, San Francisco (C.S.L., A.K.S.).

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BGBaylor-Hopkins Center For Mendelian Genomics
Baylor-Hopkins Center For Mendelian Genomics
LWLevi B Watkin
Levi B Watkin
BJBirthe Jessen
Birthe Jessen
WWWojciech Wiszniewski
Wojciech Wiszniewski
TVTimothy J Vece
Timothy J Vece
ASAnthony K Shum
Anthony K Shum

28 July 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ZDZimu Deng
Zimu Deng
ZCZhenlu Chong
Zhenlu Chong
CLChristopher S. Law
Christopher S. Law
KMKojiro Mukai
Kojiro Mukai
FHFrances O. Ho
Frances O. Ho
ASAnthony K. Shum
Anthony K. Shum
Pathogenic COPA variants cause a Mendelian syndrome of immune dysregulation with elevated type I interferon signaling. COPA is a subunit of coat protein complex I (COPI) that mediates Golgi to ER transport. Missense mutations of the COPA WD40 domain impair binding and sorting of proteins targeted for ER retrieval, but how this causes disease remains unknown. Given the importance of COPA in Golgi–ER transport, we speculated that type I interferon signaling in COPA syndrome involves missorting of STING. We show that a defect in COPI transport causes ligand-independent activation of STING. Furthermore, SURF4 is an adapter molecule that facilitates COPA-mediated retrieval of STING at the Golgi. Activated STING stimulates type I interferon–driven inflammation in CopaE241K/+ mice that is rescued in STING-deficient animals. Our results demonstrate that COPA maintains immune homeostasis by regulating STING transport at the Golgi. In addition, activated STING contributes to immune dysregulation in COPA syndrome and may be a new molecular target in treating the disease.

4 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
KMKojiro Mukai
Kojiro Mukai
EOEmari Ogawa
Emari Ogawa
RURei Uematsu
Rei Uematsu
YKYoshihiko Kuchitsu
Yoshihiko Kuchitsu
FKFumika Kiku
Fumika Kiku
TTTomohiko Taguchi
Tomohiko Taguchi
Coat protein complex I (COP-I) mediates the retrograde transport from the Golgi apparatus to the endoplasmic reticulum (ER). Mutation of the COPA gene, encoding one of the COP-I subunits (α-COP), causes an immune dysregulatory disease known as COPA syndrome. The molecular mechanism by which the impaired retrograde transport results in autoinflammation remains poorly understood. Here we report that STING, an innate immunity protein, is a cargo of the retrograde membrane transport. In the presence of the disease-causative α-COP variants, STING cannot be retrieved back to the ER from the Golgi. The forced Golgi residency of STING results in the cGAS-independent and palmitoylation-dependent activation of the STING downstream signaling pathway. Surf4, a protein that circulates between the ER/ ER-Golgi intermediate compartment/ Golgi, binds STING and α-COP, and mediates the retrograde transport of STING to the ER. The STING/Surf4/α-COP complex is disrupted in the presence of the disease-causative α-COP variant. We also find that the STING ligand cGAMP impairs the formation of the STING/Surf4/α-COP complex. Our results suggest a homeostatic regulation of STING at the resting state by retrograde membrane traffic and provide insights into the pathogenesis of COPA syndrome.

1 April 2018 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
JTJessica L. Tsui
Jessica L. Tsui
OEOscar A. Estrada
Oscar A. Estrada
ZDZimu Deng
Zimu Deng
KWKristin M. Wang
Kristin M. Wang
CLChristopher S. Law
Christopher S. Law
ASAnthony K. Shum
Anthony K. Shum
The COPA syndrome is a monogenic, autoimmune lung and joint disorder first identified in 2015. This study sought to define the main pulmonary features of the COPA syndrome in an international cohort of patients, analyse patient responses to treatment and highlight when genetic testing should be considered.We established a cohort of subjects (N=14) with COPA syndrome seen at multiple centres including the University of California, San Francisco, CA, USA. All subjects had one of the previously established mutations in theCOPAgene, and had clinically apparent lung disease and arthritis. We analysed cohort characteristics using descriptive statistics.All subjects manifested symptoms before the age of 12 years, had a family history of disease, and developed diffuse parenchymal lung disease and arthritis. 50% had diffuse alveolar haemorrhage. The most common pulmonary findings included cysts on chest computed tomography and evidence of follicular bronchiolitis on lung biopsy. All subjects were positive for anti-neutrophil cytoplasmic antibody, anti-nuclear antibody or both and 71% of subjects had rheumatoid factor positivity. All subjects received immunosuppressive therapy.COPA syndrome is an autoimmune disorder defined by diffuse parenchymal lung disease and arthritis. We analysed an international cohort of subjects with genetically confirmed COPA syndrome and found that common pulmonary features included cysts, follicular bronchiolitis and diffuse alveolar haemorrhage. Common extrapulmonary features included early age of onset, family history of disease, autoantibody positivity and arthritis. Longitudinal data demonstrated improvement on chest radiology but an overall decline in pulmonary function despite chronic treatment.

20 March 2020 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ZDZimu Deng
Zimu Deng
CLChristopher S. Law
Christopher S. Law
FHFrances O Ho
Frances O Ho
KWKristin M. Wang
Kristin M. Wang
KJKirk D. Jones
Kirk D. Jones
ASAnthony K. Shum
Anthony K. Shum
COPA syndrome is a recently described Mendelian autoimmune disorder caused by missense mutations in the coatomer protein complex subunit α (COPA) gene. Patients with COPA syndrome develop arthritis and lung disease that presents as pulmonary hemorrhage or interstitial lung disease (ILD). Immunosuppressive medications can stabilize the disease, but many patients develop progressive pulmonary fibrosis, which requires life-saving measures, such as lung transplantation. Because very little is understood about the pathogenesis of COPA syndrome, it has been difficult to devise effective treatments for patients. To date, it remains unknown which cell types are critical for mediating the disease as well as the mechanisms that lead to autoimmunity. To explore these issues, we generated a CopaE241K/+ germline knock-in mouse bearing one of the same Copa missense mutations in patients. Mutant mice spontaneously developed ILD that mirrors lung pathology in patients, as well as elevations of activated cytokine-secreting T cells. In this study, we show that mutant Copa in epithelial cells of the thymus impairs the thymic selection of T cells and results in both an increase in autoreactive T cells and decrease in regulatory T cells in peripheral tissues. We demonstrate that T cells from CopaE241K/+ mice are pathogenic and cause ILD through adoptive transfer experiments. In conclusion, to our knowledge, we establish a new mouse model of COPA syndrome to identify a previously unknown function for Copa in thymocyte selection and demonstrate that a defect in central tolerance is a putative mechanism by which COPA mutations lead to autoimmunity in patients.

27 February 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
NSNoa Simchoni
Noa Simchoni
SKShogo Koide
Shogo Koide
MLMaryel Likhite
Maryel Likhite
YKYoshihiko Kuchitsu
Yoshihiko Kuchitsu
SKSenkottuvelan Kadirvel
Senkottuvelan Kadirvel
ASAnthony K. Shum
Anthony K. Shum
COPA syndrome, an autosomal-dominant inborn error of immunity, is nonpenetrant in ∼20% of individuals, with no known mediators of protection. Recent studies implicate STING in the pathogenesis of COPA syndrome. We show that the common HAQ STING allele mediates complete clinical protection. We sequenced 35 individuals with COPA mutations, 26 affected patients and 9 unaffected carriers, finding HAQ STING co-segregation with clinical nonpenetrance. Exome sequencing identified only the mutations comprising HAQ STING as variants shared by unaffected carriers and absent in patients. Experimentally, we found that HAQ STING acts dominantly to dampen COPA-dependent STING signaling. Expressing HAQ STING in patient cells rescued the molecular phenotype of COPA syndrome. Our study is the first report of a common and well-tolerated allele mediating complete clinical protection from a severe genetic disorder. Our findings redefine the diagnostic criteria for COPA syndrome, expose functional differences among STING alleles with broad scientific and clinical implications, and reveal a potential universal gene therapy approach for patients.